Refine by
Clinical Diagnosis Articles & Analysis
41 news found
Therefore, flow cytometry is widely used in clinical diagnosis and medical research, such as tumor-associated diseases, autoimmune diseases, cardiovascular diseases, inflammatory infections and infectious diseases, providing higher clinical value for differential diagnosis, treatment monitoring and condition assessment. ...
Everyone unanimously approved and applauded the exhibited products which included the PreMed 5200 liquid chromatography tandem mass spectrometry system, GeneTOF 3100 nucleic acid mass spectrometry system, ClinCap 1000 fully automated capillary electrophoresis instrument, and MSFLO benchtop mass spectrometry flow cytometer among a few.Focusing on clinical ...
Creative Enzymes, a global leader in diagnostic enzyme manufacturing and supply, is dedicated to offering a wide range of enzyme products as well as customized enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched kidney and pancreas function diagnostic enzymes for the global market. ...
In 2019, he joined Owkin where, for the past three years, he has developed AI-based solutions to optimize clinical trials. At SeqOne, Michael will lead scientific research and the development of new genomic analysis solutions to improve the clinical interpretation and diagnosis of cancer and hereditary diseases. ...
Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. ...
ByxCures
A preliminary report is then sent to the patient's clinician for review, potentially leading to diagnosis and clinical intervention. “We are incredibly excited about this important milestone as we make progress in bringing a new monitoring platform to patients who can benefit from it. ...
The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) has received guidance from the U.S. Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA’s guidance was received in written response to ...
Virusight Diagnostic, a world leader in combining artificial intelligence software and spectral technology today announced the results of a major clinical study that found its ultra-rapid, point of care Pathogens Diagnostic solution consistently delivers 96.3% accuracy when compared to the gold standard RT-PCR. ...
EEG is standard of care in the clinical diagnosis and management of many neurologic diseases and sleep disorders, yet features of clinical significance often are difficult to extract from EEG data. ...
Following the announcement of the Phase 1 clinical trial of SACT-1 in January 2022, Aptorum is pleased to announce further data updates from the trial conducted by an independent clinical contract research organization. ...
“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President ...
Diagnostic Variability of Molds in Allergy Testing: Mold allergy is usually diagnosed through clinical symptoms in addition to positive specific IgE results to mold species and/or skin prick testing. Mold allergy is difficult to diagnose for several reasons: First, molds from outdoor environment may show no seasonal variability, making the patient’s history less reliable ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology and orthopedics, today announced that it will be exhibiting at the American Urological Association ("AUA") Annual Meeting on May 13-16, 2022 in New Orleans to showcase ...
” About INSPIRE The INSPIRE trial is a Phase 2, randomized, double-blind, placebo-controlled study that enrolled patients with a clinical diagnosis of COVID-19 confirmed by laboratory testing and are in severe to critical condition requiring supplemental oxygen. ...
Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible and affordable care to different countries and their diverse systems, realities, and providers. ...
” More specifically, the testing range of T,C&A Lab encompasses the following: l Repair materials for the skeletal-muscle system such as bones, teeth, joints, and tendons l Soft tissue materials such as skin, esophagus, respiratory tract, bladder and other l Cardiovascular system materials such as artificial heart valves, blood vessels, and cardiovascular catheters l Medical ...
Furthermore, the glycoproteins and glycolipids on the cell surface can be "shed" to the surrounding environment or enter the blood circulation, which can be used as abnormal markers to provide information for clinical diagnosis. Glycoproteins in body fluids often have specific or strong or weak changes when suffering from certain diseases, which can help in ...
Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a phase 1b/2a clinical trial for SACT-1 to test the drug in neuroblastoma patients in 2022. ...
The scope of the Positron/Neusoft agreement is to further develop the utilization of its PET/CT technology and services for nuclear cardiology while expanding into the field of oncology imaging diagnostics and clinical services. The U.S. is the largest total addressable market for both cardiology and oncology fields and will continue to be Positron’s primary focus, however ...
Mr Darren Lui, President and Executive Director of Aptorum Group says, “In addition to our previous announcement of the completion of our Phase 1 clinical trial of SACT-1 on January 10, 2022, we are pleased to have received the granted patent from the USPTO on our drug candidate. ...